摘要
目的:探讨1例急性髓系白血病(acute myeloid leukemia,AML)伴新的(t8;21)变异易位即(t7;21)(p21;q22)易位患者的临床与分子生物学特点。方法:将AML患者的骨髓细胞经短期培养后按常规方法制备染色体,R显带进行核型分析;利用AML1/ETO双色双融合探针进行荧光原位杂交检测;实时荧光定量PCR法检测AML1/ETO融合基因的转录本拷贝数。结果:患者的常规细胞遗传学分析结果显示为(t7;21)(p21;q22)易位。86%的骨髓细胞为AML1/ETO融合基因阳性,融合基因转录本为51440个拷贝/10000个内参Abl基因拷贝。结论:(t7;21)(p21;q22)是一种新的(t8;21)(q22;q22)变异易位,与其他类型的(t8;21)变异易位相似,预示有良好预后。
Objective： To investigate the clinical and laboratory characteristics of one patient with AML （acute myeloid leukemia） carrying t（7;21）（p21;q22）——a new variant form of t（8;21） （p21;q22）. Methods： Cytogenetic examination was performed after culture of cells from bone marrow for 24 h. R-banding technique was used for karyotype analysis. AML1/ETO fusion gene was detected by dual-color fluorescence in situ hybridization （FISH） using AML1/ETO dual-color probes. Quantitative analysis of AML1/ETO chimeric transcripts was performed by using a real-time fluorescence-based quantitative PCR. Results： Chromosome analysis revealed a karyotype of 46, XX, t（7;21）（p21;q22）, and AML1/ETO fusion gene was found in 86% of the bone marrow cells. The AML1/ETO fusion transcript copy number was 51 440/10 000 Abl copies. Conclusion： The AML patient carrying t（7;21）（p21;q22） which is a new variant form of t（8;21）（q22;q22） may have a better prognosis.
出处
《肿瘤》
CAS
CSCD
北大核心
2012年第10期833-836,共4页
Tumor
